The FDA has approved the Magnetom Spectra 3 Tesla MRI system, from Siemens. The new system employs Tim (Total imaging...
Expert insights into key challenges in UC management
Background: Doravirine is a novel, nonnucleoside reverse transcriptase inhibitor with demonstrated efficacy in treatment-naive adults with HIV-1.
Merck Inc announced positive top-line results from two pivotal Phase III trials of the investigational, once-daily oral fixed dose combination pill of MK 8591 + Pifeltro (islatravir + doravirine) (DOR/ISL) in adults with HIV-1 infection who are virologically suppressed on different antiretroviral therapy regimens (ART; ILLUMINATE SWITCH A) or bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF; ILLUMINATE SWITCH B).
Purpose of review: The current review addresses the role of doravirine (DOR), a novel once-daily nonnucleoside reverse transcriptase inhibitor (NNRTI) in first-line therapy at a time in which multiple options are available...
Merck Inc. has announced Week 96 results from the Phase III DRIVE-FORWARD clinical trial evaluating the efficacy and safety of...
To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment-effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic...
Background: Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active against wild-type Human Immunodeficiency Virus (HIV)-1 and the most common NNRTI-resistant variants, and has a favorable and unique in vitro resistance profile.
Experts discuss the latest on ulcerative colitis guidelines, treatments and integration into clinical practice after UEGW 2023.
Objective: To compare and contrast doravirine (DOR) with other agents in the nonnucleoside reverse transcriptase inhibitor (NNRTI) class, review safety and efficacy data from both completed and ongoing clinical trials...